Although the short term results for effectiveness of these new generation devices are encouraging, 30 31 32 their long term safety profile in people with and without diabetes is still ill defined.
However, there is a controversy about their complete efficacy and long-term safety in improving the patients symptomatically [12].
The ability to use these lower doses could have major implications for the delivery, cost, and accessibility of anti-CD20 mAbs, but further studies will be needed to determine efficacy, optimal dosing schedule, and long-term safety in RA patients.
However, post-approval trials with extensive patient exposure are needed to generate knowledge of more patient-specific clinical effectiveness and long-term safety, in particular with respect to rare adverse reactions.
The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) is a unique opportunity to evaluate the prospective, long-term clinical safety and effectiveness of the anti-IgE antibody omalizumab (Xolair) in real-world clinical practice.
We performed a systematic review of the literature to determine the incidence of CML relapse, to identify possible factors relapse rates and to evaluate the long-term safety in CML patients with stable undetectable BCR-ABL transcript level who discontinued TKIs.
While numerous trials have shown robust safety of SSRIs in adults, limited data are available on their short- and long-term safety in adolescents.
Nevertheless, the long-term safety in these patients is still unknown and needs further evaluation.
Moreover, the long-term safety in clinical routine life of direct oral anticoagulants is not well-known.
Limited data specifically address metformin's long-term safety in patients with mild-to-moderate renal failure (46– 48).
